Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
H. Marzo-Ortega, D. McGonagle, P. O’Connor, P. Emery.
Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study.
Arthritis Rheum, 44 (2001), pp. 2112-2117
[2.]
J.D. Gorman, K.E. Sack, J.C. Davis.
Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
N Engl J Med, 346 (2002), pp. 1349-1356
[3.]
J. Brandt, A. Khariouzov, J. Listing, H. Haibel, H. Sörensen, L. Grassnickel, et al.
Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
Arthritis Rheum, 48 (2003), pp. 1667-1675
[4.]
J.C. Davis, D. Van der Heijde, J. Braun, M. Dougados, J. Cush, D.O. Clegg, et al.
Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
Arthritis Rheum, 48 (2003), pp. 3230-3236
[5.]
A. Calin, B.A.C. Dijkmans, P. Emery, M. Hakala, J. Kalden, M. Leirisalo-Repo, et al.
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.
Ann Rheum Dis, 63 (2004), pp. 1594-1600
[6.]
Davis JC, Van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Sustained efficacy of etanercerpt (Enbrel) in ankylosing spondylitis up to 18 months [abstract]. ACR; 2004, 16-21 October; San Antonio.
[7.]
M. Rudwaleit, X. Baraliakos, J. Brandt, J. Sieper, J. Braun.
Serial magnetic resonance imaging in ankylosing spondylitis during treatment with the anti-TNF blocking agent etanercept. ACR San Antonio (Tejas) 16-21 octubre 2004.
Arthritis Rheum, (2004),
[8.]
J. Braun, X. Baraliakos, W. Golder, J. Brandt, M. Rudwaleit, J. Listing, et al.
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system.
Arthritis Rheum, 48 (2003), pp. 1126-1136
[9.]
H. Marzo-Ortega, D. McGonagle, G. Haugeberg, M.J. Green, S.P. Stewart, P. Emery.
Bone mineral density improvement in spondyloarthropathy after treatment with etanercept.
Ann Rheum Dis, 62 (2003), pp. 1020-1021
[10.]
J.E. Gottenberg, F. Merle-Vincent, F. Bentaberry, Y. Allanore, F. Berenbaum, B. Fautrel, et al.
Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy.
Arthritis Rheum, 48 (2003), pp. 2019-2024
[11.]
P.J. Mease, B.S. Goffe, J. Metz, A. VanderStoep, B. Finck, D.J. Burge.
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.
Lancet, 356 (2000), pp. 385-390
[12.]
P.J. Mease, A.J. Kivitz, F.X. Burch, E.L. Siegel, S.B. Cohen, P. Ory, et al.
Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.
Arthritis Rheum, 50 (2004), pp. 2264-2272
[13.]
P.J. Mease, E.M. Ruderman, C.T. Ritchlin, P. Ory, W.T. Tsuji.
Etanercept in psoriatic arthritis: sustained improvement in joint and skin disease and inhibition of radiographic progression at 2 years [abstract].
Ann Rheum Dis, 63 (2004), pp. 99-100
[14.]
E.C. Keysonte, M.H. Schiff, J.M. Kremer, S. Kafka, M. Lovy, T. De Vries, et al.
Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
Arthritis Rheum, 50 (2004), pp. 353-363
[15.]
J. Brandt, A. Khariouzov, J. Listing, H. Haibel, H. Sorensen, S. Rudwaleit, et al.
Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept.
J Rheumatol, 31 (2004), pp. 531-538
[16.]
R. Inman, J. Whitmore, A. Solinger.
Treatment of adult patients with juvenile- onset ankylosing spondylitis.
Ann Rheum Dis, 63 (2004), pp. 390.
Copyright © 2005. Elsevier España S.L. Barcelona
